These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35978659)

  • 21. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome.
    Milic J; Barbieri S; Gozzi L; Brigo A; Beghé B; Verduri A; Bacca E; Iadisernia V; Cuomo G; Dolci G; Yaacoub D; Aprile E; Belli M; Venuta M; Meschiari M; Sebastiani G; Clini E; Mussini C; Lonardo A; Guaraldi G; Raggi P
    Open Forum Infect Dis; 2022 Mar; 9(3):ofac003. PubMed ID: 35146047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Thyroid Function in Childhood Obesity: A Vicious Circle?
    Calcaterra V; Degrassi I; Taranto S; Porro C; Bianchi A; L'assainato S; Silvestro GS; Quatrale A; Zuccotti G
    Children (Basel); 2024 Feb; 11(2):. PubMed ID: 38397356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAFLD in Obese Children: A Challenging Definition.
    Di Sessa A; Guarino S; Umano GR; Arenella M; Alfiero S; Quaranta G; Miraglia Del Giudice E; Marzuillo P
    Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33806784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAFLD and CKD: An Updated Narrative Review.
    Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.
    Kaya E; Yilmaz Y
    Ther Adv Endocrinol Metab; 2022; 13():20420188221139650. PubMed ID: 36533185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
    Prasoppokakorn T; Pitisuttithum P; Treeprasertsuk S
    J Clin Transl Hepatol; 2021 Dec; 9(6):939-946. PubMed ID: 34966657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions.
    Alshehade S; Alshawsh MA; Murugaiyah V; Asif M; Alshehade O; Almoustafa H; Al Zarzour RH
    Life Sci; 2022 Sep; 305():120732. PubMed ID: 35760093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
    Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
    Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011-2018.
    Wong RJ; Cheung R
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e610-e613. PubMed ID: 33493692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic dysfunction-associated fatty liver disease and osteoporosis: the mechanisms and roles of adiposity.
    Tao J; Li H; Wang H; Tan J; Yang X
    Osteoporos Int; 2024 Aug; ():. PubMed ID: 39136721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
    Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
    Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.
    Mărginean CO; Meliț LE; Săsăran MO
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multiple mechanisms and therapeutic significance of rutin in metabolic dysfunction-associated fatty liver disease (MAFLD).
    Wang Q; Zhang Y; Lu R; Zhao Q; Gao Y
    Fitoterapia; 2024 Oct; 178():106178. PubMed ID: 39153555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.
    Suoh M; Esmaili S; Eslam M; George J
    Hepatol Int; 2024 Oct; ():. PubMed ID: 39412611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.